Navigation Links
EntreMed to Present at ThinkEquity Partners' 5th Annual Growth Conference
Date:9/14/2007

ROCKVILLE, Md., Sept. 14 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the ThinkEquity Partners' 5th Annual Growth Conference, to be held at the St. Regis Hotel, in San Francisco, California, September 17-20, 2007. Mr. Burns' presentation is scheduled for Wednesday, September 19, 2007 at 2:00 p.m. (Pacific time).

Mr. Burns' live presentation will be web cast and can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. Panzem(R) is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

CONTACT:

Ginny Dunn

Associate Director

Corporate Communications & Investor Relations

EntreMed, Inc.

240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... ... (PRWEB) May 16, 2017 , ... ... Chinese Association of Orthopaedic Surgeons (CAOS), long-standing development partners Invibio Biomaterial Solutions, ... interbody spine surgery workshop to help expand knowledge of the implantation of ...
(Date:5/15/2017)... ... May 15, 2017 , ... ... Advanced Lift Contouring Cream, a gravity-shattering cream with a patented formula, clinically proven ... to bring the Advanced Lift Contouring Cream to our already innovative ELEVATE product ...
(Date:5/12/2017)... May 12, 2017  Eli Lilly and Company (NYSE: ... an investigational treatment for the prevention of episodic ... three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) ... monthly migraine headache days compared to placebo at ... results from these three studies bring us one ...
(Date:5/11/2017)... ... 2017 , ... The key to unlocking the cause of Multiple Sclerosis may ... neurological disorder that can rob people of their ability to see, speak, and walk. ... arises from a genetic tendency towards the disease combined with an unidentified environmental trigger. ...
Breaking Biology Technology:
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
Breaking Biology News(10 mins):